Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Through Alimta Lens, OSI Views Positive Near-term Advantages For Tarceva In Lung Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval of Lilly’s Alimta in first-line NSCLC and recent data showing it is ineffective in squamous histologies could give Tarceva a leg up in second-line setting.

You may also be interested in...



ASCO Preview Highlights Study Of Alimta For First-Line NSCLC

Maintenance therapy with Lilly’s pemetrexed shows increase in progression-free survival in the only drug-related abstract in ASCO’s press call.

OSI Bullish On Increased Tarceva Sales

Oncologic is “entrenched” in the market, not greatly vulnerable to competition from Erbitux, CEO Goddard tells investors.

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel